Aduhelm Approval Raises Concerns About US FDA Leadership, Senate Finance Chair Suggests

 
• By Cathy Kelly
Sen. Ron Wyden at 10 June 2021 hearing (screenshot)
Sen. Ron Wyden, D-OR, Points To Janet Woodcock's Responsibility For Approval Based On 'Skimpy' Evidence • Source: screenshot

More from US FDA

More from Agency Leadership